Canada markets close in 6 hours 10 minutes

Satellos Bioscience Inc. (MSCL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4950+0.0400 (+8.79%)
As of 09:31AM EDT. Market open.
Full screen
Previous Close0.4550
Open0.4950
Bid0.4500 x N/A
Ask0.4950 x N/A
Day's Range0.4950 - 0.4950
52 Week Range0.4000 - 2.5000
Volume1,000
Avg. Volume31,278
Market Cap16.334M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6040
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Satellos Bioscience Announces In-Licensing of New Patent Application

    Toronto, Ontario--(Newsfile Corp. - June 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has licensed a provisional patent application, recently filed with the United States Patent and Trademark Office and titled "MODULATION OF SATELLITE CELL POLARITY AND ASYMMETRIC CELL DIVISION," from the Ottawa Hospital Research

  • GlobeNewswire

    Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3nbZJuOThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accepting 1x1 manag

  • Newsfile

    Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society

    Toronto, Ontario--(Newsfile Corp. - June 22, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been admitted as a Fellow of the Royal Society, the UK's national science academy and a Fellowship of the world's most revered scientists. With admission